In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide.
This study reports on the release of a novel natriuretic peptide, CD-NP, from an in situ polymer precipitation delivery system. Following extensive screening of in-vitro release profiles, an in-vivo evaluation of the efficacy of the delivery system was carried out in Wistar rats. Gel injection was p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23441143/?tool=EBI |
| _version_ | 1818403909695176704 |
|---|---|
| author | Soo Ghim Lim Subbu S Venkatraman John C Burnett Horng H Chen |
| author_facet | Soo Ghim Lim Subbu S Venkatraman John C Burnett Horng H Chen |
| author_sort | Soo Ghim Lim |
| collection | DOAJ |
| description | This study reports on the release of a novel natriuretic peptide, CD-NP, from an in situ polymer precipitation delivery system. Following extensive screening of in-vitro release profiles, an in-vivo evaluation of the efficacy of the delivery system was carried out in Wistar rats. Gel injection was performed subcutaneously on the back of the rats. A secondary messenger, cyclic Guanosine 3'5' Monophosphate (cGMP), was tested for verification of CD-NP bioactivity, in addition to direct measurements of CD-NP levels in plasma and urine using a radio-immuno assay. Plasma evaluation showed an elevated level of CD-NP over 3 weeks' duration. Unexpectedly, plasma cGMP level followed a decreasing trend over the same duration despite high CD-NP level. Loss of drug bioactivity was ruled out as a high level of CD-NP and cGMP excretion was observed in the treatment group as compared to baseline readings. This unexpected low-plasma cGMP levels and high-urinary cGMP excretion suggest that there might be other compensatory responses to regulation of the CDNP bioactivity as a result of the high drug dosing. The results stress the importance of assessing the overall bioactivity of released drug (in-vivo) concurrently in addition to measuring its concentrations, to determine the correct release profile. |
| first_indexed | 2024-12-14T08:31:45Z |
| format | Article |
| id | doaj.art-98b25912d8324f0482bf5cc48f22e256 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T08:31:45Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-98b25912d8324f0482bf5cc48f22e2562022-12-21T23:09:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5248410.1371/journal.pone.0052484In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide.Soo Ghim LimSubbu S VenkatramanJohn C BurnettHorng H ChenThis study reports on the release of a novel natriuretic peptide, CD-NP, from an in situ polymer precipitation delivery system. Following extensive screening of in-vitro release profiles, an in-vivo evaluation of the efficacy of the delivery system was carried out in Wistar rats. Gel injection was performed subcutaneously on the back of the rats. A secondary messenger, cyclic Guanosine 3'5' Monophosphate (cGMP), was tested for verification of CD-NP bioactivity, in addition to direct measurements of CD-NP levels in plasma and urine using a radio-immuno assay. Plasma evaluation showed an elevated level of CD-NP over 3 weeks' duration. Unexpectedly, plasma cGMP level followed a decreasing trend over the same duration despite high CD-NP level. Loss of drug bioactivity was ruled out as a high level of CD-NP and cGMP excretion was observed in the treatment group as compared to baseline readings. This unexpected low-plasma cGMP levels and high-urinary cGMP excretion suggest that there might be other compensatory responses to regulation of the CDNP bioactivity as a result of the high drug dosing. The results stress the importance of assessing the overall bioactivity of released drug (in-vivo) concurrently in addition to measuring its concentrations, to determine the correct release profile.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23441143/?tool=EBI |
| spellingShingle | Soo Ghim Lim Subbu S Venkatraman John C Burnett Horng H Chen In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS ONE |
| title | In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. |
| title_full | In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. |
| title_fullStr | In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. |
| title_full_unstemmed | In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. |
| title_short | In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. |
| title_sort | in vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23441143/?tool=EBI |
| work_keys_str_mv | AT sooghimlim invivoevaluationofaninsitupolymerprecipitationdeliverysystemforanovelnatriureticpeptide AT subbusvenkatraman invivoevaluationofaninsitupolymerprecipitationdeliverysystemforanovelnatriureticpeptide AT johncburnett invivoevaluationofaninsitupolymerprecipitationdeliverysystemforanovelnatriureticpeptide AT hornghchen invivoevaluationofaninsitupolymerprecipitationdeliverysystemforanovelnatriureticpeptide |